Michael J. Schell

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study

Jacob G. Scott, Anders Berglund, Michael J. Schell et al. · The Lancet Oncology · 2016 · 469 citations · Full text

Medicine, Oncology, Radiation Oncology +16

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

Richard D. Kim, Vincent Chung, Olatunji B. Alese et al. · JAMA Oncology · 2020 · 449 citations · Full text

Medicine, Oncology, Pharmacology +16

Successful Intermittent Chemoprophylaxis for<i>Pneumocystis carinii</i>Pneumonitis

Walter T. Hughes, Gaston K. Rivera, Michael J. Schell et al. · New England Journal of Medicine · 1987 · 405 citations

Medicine, Pharmacology, Pharmacotherapy +10

The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: who gets the message about breast cancer screening?

Michael O’Malley, J A Earp, Sarah T. Hawley et al. · American Journal of Public Health · 2001 · 266 citations · Full text

Medicine, Population Health Sciences, Preventive Medicine +17

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

Geoffrey T. Gibney, Ragini R. Kudchadkar, Ronald C. DeConti et al. · Clinical Cancer Research · 2014 · 256 citations · Full text

Medicine, Immunology, Oncology +17